Mohammed Islam, MD
Neuromusculoskeletal Medicine & OMM · Elmhurst, NYNPI 1245205012
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $959 of the $1,106 with a category attached, or 86.7%. 11 manufacturers reported payments, led by Neurocrine Biosciences, Inc. at 49.6% of the total. Reporting peaked in 2024 at $428 and has fallen 59.7% since, to $173 in 2025.
Across 35 payments — averaging $31.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$549
- Abbott$165
- AstraZeneca$140
- Teva Pharmaceuticals USA, Inc.$87
- UCB, Inc.$68
- Organogenesis Inc.$26
- plus $70 from 5 others
What the payments were for
- Food & beverage$95987%
- Education$14713%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 16 | $549 |
| Abbott | 6 | $165 |
| AstraZeneca(2 entities) | 3 | $140 |
| Teva Pharmaceuticals USA, Inc. | 1 | $87 |
| UCB, Inc. | 3 | $68 |
| Organogenesis Inc. | 1 | $26 |
| Sanofi | 1 | $22 |
| SK Life Science, Inc. | 1 | $18 |
| Eisai Inc. | 1 | $17 |
| Boston Scientific | 1 | $12 |
| Aroa Biosurgery Incorporated | 1 | $2 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INGREZZA$124
How this compares
$1,106 in reported general payments places this provider in the 85th percentile of 46 neuromusculoskeletal medicine & omm providers in New York.
See all neuromusculoskeletal medicine & omm providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levetiracetam | 134 | $4,646 |
| Donepezil Hcl | 351 | $4,374 |
| Memantine Hcl | 127 | $2,474 |
| Pregabalin | 39 | $2,219 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 119 | $2,195 |
| Lacosamide | 26 | $2,025 |
| Gabapentin | 208 | $1,708 |
| RivastigmineRivastigmine Tartrate | 18 | $1,145 |
| Divalproex Sodium ErDivalproex Sodium | 11 | $911 |
| Nortriptyline Hcl | 66 | $742 |
| Carbamazepine ErCarbamazepine | 13 | $715 |
| Meclizine Hcl | 80 | $705 |
| Diclofenac Sodium | 19 | $676 |
| Primidone | 42 | $578 |
| Pramipexole DihydrochloridePramipexole Di-Hcl | 31 | $545 |
Paid to pharmacies, not to this prescriber.
Other neuromusculoskeletal medicine & omm in Elmhurst
- Mehri SonghorianElmhurst$8K
- Clair CascellaNew Hyde Park$5K
- Richard ChmielewskiNew Hartford$3K
- Brian WaldronNew York$2K
- Kerin HausknechtLynbrook$2K
- Michael FlorekNew York$1K
- Patricia HartKirkville$936
- Alan DavidWhite Plains$730
- Jerry KaplanHuntington Station$647
- James LiguoriNew Hyde Park$509
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.